Introduction {#Sec1}
============

For over 60 years, warfarin has been the mainstay anticoagulant used in the prevention and treatment of thromboembolic complications in patients with atrial fibrillation, venous thromboembolism, prosthetic heart valves, and coronary artery disease (Nutescu et al. [@CR17]). Because of its narrow therapeutic index and the substantial interpatient variability associated with its dosing, careful monitoring of warfarin is strongly recommended by current practice guidelines to minimize the risks associated with warfarin's inadequate dosing and ensure optimal outcomes for anticoagulated patients (Horton and Bushwick [@CR8]; You et al. [@CR23]). Despite its wide-spread use, management of patients on warfarin treatment is associated with many challenges. These challenges include therapeutic dose inter- and intra-patient variability, drug and food interactions, environmental factors, co-morbidities, and narrow therapeutic index (Nutescu et al. [@CR17]). Accordingly, close monitoring and individualized dosing based on International normalized ratio (INR) measurement is warranted to confirm effective level of anticoagulation (Ageno et al. [@CR1]).

Warfarin is administered as a racemic mixture, the R and S enantiomers. The more potent, S enantiomer, is subject to approximately 90 % oxidative metabolism, mainly through the Cytochrome P450 2C9 (CYP2C9) enzyme of the Cytochrome P450 system and to a minor extent by CYP3A4. On the other hand, the less potent, R enantiomer, is subject to approximately 60 % oxidative metabolism, primarily through CYP1A2 and CYP3A4, and to a minor extent through CYP2C19 (Kaminsky and Zhang [@CR9]; Miners and Birkett [@CR15]; Cropp and Bussey [@CR5]).

Rifampin is a widely used antimicrobial for the treatment of challenging and life-threatening infections such as tuberculosis, meningitis, osteomyelitis and endocarditis (Baciewicz et al. [@CR3]). Due to its proven efficacy in the management of infective endocarditis, American Heart association (AHA), and the European Society for cardiology (ESC),recommend rifampin in treatment of prosthetic valve endocarditis caused by Coagulase-Negative Staphylococci species in combination with other antimicrobial agents (Gould et al. [@CR6]; Newburger et al. [@CR16]). Rifampin is known to have major interactions with several medications due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19 (Horn et al. [@CR7]; Ohno et al. [@CR18]). Rifampin's concomitant use with warfarin results in a clinically significant drug--drug interaction. This interaction leads to accelerated warfarin's clearance and ultimately a reduction in its anticoagulant effect (Strayhorn et al. [@CR21]; Baciewicz et al. [@CR3]). There are several, well-documented cases of potential interactions during concurrent rifampin-warfarin use (Lee and Thrasher [@CR12]; Martins et al. [@CR14]; Krajewski [@CR11]; Maina et al. [@CR13]). This interaction affects warfarin dose required to achieve and maintain therapeutic INR and may increase this dose up to six times to reach target therapeutic INR. If warfarin dose is not adjusted accordingly, this may lead to subtherapeutic INR values and increase in the risk of clinical complications (Kim et al. [@CR10]; Tong et al. [@CR22]; Krajewski [@CR11]; Lee and Thrasher [@CR12]). This interaction remains clinically significant during, and weeks after discontinuation of rifampin. Additionally, risk of bleeding after rifampin discontinuation has been reported (Martins et al. [@CR14]).

The aim of this case report is to address the effect of rifampin--warfarin interaction in a patient with endocarditis who has been receiving a stable and therapeutic warfarin dose for mechanical heart valve replacement. The patient has provided consent for the use of his personal and medical information in this case report.

Presentation {#Sec2}
============

A 34-year-old Srilankan female with a history of rheumatic heart disease, underwent mitral valve replacement in 1994 and was on anticoagulation ever since with warfarin and a target INR of (2.5--3.5). She was maintained on warfarin weekly dose of 52.5 mg (7.5 mg daily) since she started follow-up at our pharmacist-managed anticoagulation clinic in late 2013.

On the 23rd of October, 2014, the patient started to have fever with chills and was admitted to the hospital and diagnosed with prosthetic valve infective endocarditis. Initially, the patient was started on vancomycin (1800 mg/day), gentamicin (80 mg/day), ceftriaxone (2 g/day) and rifampin (600 mg/day). The patient was using her usual warfarin dose (7.5 mg daily) and her INR was 2.6. Two days later, and she complained of heavy menses and her hemoglobin dropped to 7.5 g/dl. INR increased to 4.4 at that time and warfarin was stopped.

Three days later, some changes were made to her antibiotic regimen where vancomycin was replaced by daptomycin (300 mg/day). Her gentamycin was stopped after 3 weeks from its initiation while the rest of the antibiotics (daptomycin, ceftriaxone and rifampin) were continued for three more weeks to complete a six-week course.

After being held for 5 days due to the bleeding and drop in hemoglobin, warfarin was restarted and an INR of 1.6 was recorded at that time. Since warfarin resumption, the patient's INR became subtherapeutic likely due to the interaction with rifampin. Conservative increments of warfarin dose were made during her hospitalization period which continued for almost a month. Upon discharge on the 18th of November, INR was 1.3 and warfarin weekly dose was 105 mg (15 mg/day), she was then followed-up again at the anticoagulation clinic and was bridged with therapeutic dose enoxaparin (1 mg/kg subcutaneous every 12 h). Warfarin weekly dose was increased gradually from 105 to 155 mg over the following 2 weeks but her INR remained subtherapeutic at all time and increased slightly from 1.3--1.8.

On the 3rd of December, the patient had symptoms of palpitations and her electrocardiogram showed atrial flutter with rapid ventricular response of 147 beats per minute and she was admitted again to the cardiac care unit for rate control were she was maintained on metoprolol (50 mg/day). Six days later, the patient's antibiotics including rifampin were stopped after completing a total of 6-week treatment course for endocarditis. The following day, she was discharged with an INR of 2.4 and a warfarin weekly dose of 210 mg daily (30 mg/day). The first significant change in her INR was a drop to 1.9 (no change in dosing was made at this point) and she was followed-up every 2--3 days. Her INR readings gradually increased but were all in therapeutic range (INR on 17/12/2014 was 3.3). Four days later, (11 days post-antibiotics discontinuation, the patient had a supratherapeutic INR of 10.2 for which warfarin was held for 2 days and then resumed at a reduced-dose of 7.5 mg/day (her routine dose prior to rifampin initiation). Patient's INR did not adequately respond to this dose reduction and became subtherapeutic. Warfarin dose was increased gradually while bridging with therapeutic dose enoxaparin till she reached a maintenance dose of (10 mg daily except 15 mg twice/week) (a weekly dose of 80 mg) on 15/1/2015 where her INR reached 2.5 (Fig. [1](#Fig1){ref-type="fig"}).

In summary, warfarin dose was increased from 52.5 to 210 mg/week over the course of the 6-week treatment with antibiotics for her infective endocarditis. Due to the patient's risk of stroke and the difficulty to reach therapeutic INR, she was bridged using enoxaparin. The patient's INR remained subtherapeutic throughout the whole period when she received rifampin concomitantly with warfarin, and reached 2.4 by the end of rifampin therapy. Anticoagulation management was challenging in the period following the end of her rifampin therapy, and multiple dose adjustments starting with an increase and followed by gradual reduction were required till she was stable on an 80 mg/week warfarin dose 5 weeks post-rifampin therapy.

Discussion {#Sec3}
==========

In this case report, we observed the challenging management of warfarin therapy when rifampin therapy along with other antibiotics (ceftriaxone, gentamicin and daptomycin) were used concomitantly in a patient previously stable on anticoagulation therapy with warfarin for stroke prevention from her mechanical mitral valve replacement. While on rifampin, she required about fourfold increase in her warfarin dose and the addition of bridging therapy using low molecular weight heparin (LMWH) to maintain proper anticoagulation due to failure in achieving therapeutic INR with warfarin. After discontinuation of rifampin, the drug--drug interaction effect remained for almost 5 weeks. After the offset of rifampin effect, warfarin maintenance dose was noticed to be 150 % higher than its baseline prior to rifampin initiation (80 vs 52.5 mg/week). It is also important to note that the sudden elevation and drop in INR associated with the initiation and discontinuation of the antibiotic treatment, respectively is likely mediated by the interaction between warfarin and ceftriaxone. A previous report has shown that concomitant use of ceftriaxone and warfarin can lead to a significant elevation in INR and warfarin anticoagulant effect (Clark and Burns [@CR4]).

Several reports have previously described the interaction between rifampin and warfarin and the effect of rifampin on the anticoagulation effect of warfarin during concomitant use of both medications (Lee and Thrasher [@CR12]; Martins et al. [@CR14]; Krajewski [@CR11]; Maina et al. [@CR13]). Lee et al. described a case for a patient who was started on rifampin for active tuberculosis and was started on warfarin 4 months later for left ventricular thrombus. The warfarin dosage required to attain therapeutic INR was significantly higher when the patient received concomitant rifampin (233 % higher) than the dose required after rifampin discontinuation (Lee and Thrasher [@CR12]). Similar reports were described by others (Self and Mann [@CR20]; Almog et al. [@CR2]).

Additional case studies described patients who were started on rifampin 600 mg and warfarin around the same time. The warfarin dose was reduced by about 50 % to maintain therapeutic INR after discontinuation of rifampin (Krajewski [@CR11]; Romankiewicz and Ehrman [@CR19]).

Other reports have described the interaction between warfarin and rifampin in patients already on chronic warfarin therapy (Martins et al. [@CR14]; Tong et al. [@CR22]; Kim et al. [@CR10]). Similar to our case report, these reports described the interaction resulting from the addition of rifampin in patients already receiving chronic warfarin therapy. Sequential increase in warfarin dose was required to reach therapeutic level with frequent INR monitoring. After discontinuation of rifampin, the warfarin dosage requirement was reduced gradually to avoid supratherapeutic INR until reaching therapeutic level.

Collectively, all previously described case studies and case series agree on the difficulty of achieving therapeutic level of anticoagulation despite escalation of warfarin dose due to the interaction with rifampin. The increments recorded in warfarin dose vary between twofold to sixfold compared to the dose required when patient is not on rifampin. The onset of interaction and the requirement to increase warfarin dose seem to have faster timeline (7--14 days) compared to the offset of the interaction which may require tapering the warfarin dose down over weeks. There are wide inter-patient variability in the extent, onset and offset of the warfarin-rifampin interaction.

Conclusion {#Sec4}
==========

This case study confirms previously reported studies on the interaction between warfarin and rifampin. It also demonstrates that this interaction is clinically significant and can be very critical in high-risk patients such as those receiving warfarin for mechanical valve replacement. Our findings suggest the importance of close monitoring of warfarin therapy during and after the use of rifampin to minimize the risks of under and over-anticoagulation and improve the safety and efficacy of warfarin therapy.Fig. 1This *graph* represents the daily warfarin dose, INR, and concomitant rifampin therapy over time. The *x-axis* represents time when the INR was measured. The left *y-axis* represents the INR units and is shown by the *black diamond points*. The right *Y-axis* represents warfarin dose administered in milligrams/day and is shown by the *vertical bars*. The therapeutic range is indicated between the *two* *dotted lines* (2.5--3.5). The time period of concomitant rifampin administration is shown as the horizontal solid 2-way arrow
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